ANIX Anixa Biosciences, Inc.
USHealthcareAs of 2026-07-10 11:15
Why ANIX matters now
Anixa Biosciences, Inc. (ANIX) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.98 with -7.61% on the session and $101.2M in market capitalization; recent performance reads 1-month +8.99% and YTD -6.73%.
The latest financial table shown here is Q2 2026, with revenue of $0.00, net income of $-2.6M, and EPS of $-0.07. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -7.2%.
The latest indexable market news headline is "Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $4.00; recent insider activity includes Titterton Lewis H jr filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
6.75
P/S
0.00
EV/EBITDA
-9.68
DCF Value
$0.03
FCF Yield
-7.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-65.7%
ROA
-67.8%
ROIC
-79.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $0.00 | $-2.6M | $-0.07 |
| Q1 2026 | $0.00 | $-2.6M | $-0.08 |
| Q4 2025 | $0.00 | $-2.7M | $-0.08 |
| FY 2025 | $0.00 | $-10.9M | $-0.34 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$5.83
Target (Median)
$4.00
Target Range
$3.50 - $10.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.60
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.